Search

Viking Therapeutics Inc

Отворен

СекторЗдравеопазване

34.15 3.14

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

32.61

Максимум

34.95

Ключови измерители

By Trading Economics

Приходи

30M

-128M

EPS

-1.1

Служители

65

EBITDA

30M

-128M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+170.84% upside

Дивиденти

By Acuity

Следващи печалби

21.10.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-126M

3.9B

Предишно отваряне

31.01

Предишно затваряне

34.15

Настроения в новините

By Acuity

50%

50%

150 / 340 Класиране в Healthcare

Viking Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.08.2026 г., 19:56 ч. UTC

Social Media

Viking Therapeutics Inc shares are lower today, continuing a decline since Friday. Social media discussions highlight anticipation for upcoming data before Labor Day.

20.08.2026 г., 20:06 ч. UTC

Macro Event
Social Media

Viking Therapeutics Inc shares are lower, impacted by labor market data and heightened volatility, despite social media discussions suggesting potential recovery from a clinical trial.

19.08.2026 г., 23:16 ч. UTC

Viking Therapeutics Inc shares are higher in after-market hours, reflecting a gain since Wednesday's close and remaining above the 20-day moving average.

18.08.2026 г., 19:16 ч. UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17.08.2026 г., 23:06 ч. UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14.08.2026 г., 23:06 ч. UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13.08.2026 г., 23:16 ч. UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12.08.2026 г., 23:26 ч. UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7.08.2026 г., 19:36 ч. UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6.08.2026 г., 23:16 ч. UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5.08.2026 г., 22:51 ч. UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4.08.2026 г., 23:02 ч. UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3.08.2026 г., 23:06 ч. UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31.07.2026 г., 23:51 ч. UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30.07.2026 г., 23:56 ч. UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29.07.2026 г., 23:21 ч. UTC

Social Media
News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28.07.2026 г., 23:11 ч. UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27.07.2026 г., 23:56 ч. UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25.07.2026 г., 00:01 ч. UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24.07.2026 г., 21:01 ч. UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23.07.2026 г., 23:46 ч. UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22.07.2026 г., 23:36 ч. UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Сравнение с други в отрасъла

Ценова промяна

Viking Therapeutics Inc Прогноза

Ценова цел

By TipRanks

170.84% нагоре

12-месечна прогноза

Среден 90 USD  170.84%

Висок 114 USD

Нисък 65 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Viking Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

15

Купи

0

Задържане

0

Продай

Настроение

By Acuity

150 / 340 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat